The polypeptide diazepam binding inhibitor (DBI) displays epileptogenic activity by binding to benzodiazepine receptors. We analyzed DBI concentrations in the plasma of pediatric and adult epileptic patients, as a possible peripheral marker in epilepsy. DBI plasma concentrations are significantly higher (+ 62%, P <0.001) in adult patients and slightly but significantly higher (+ 15%, P <0.01) in pediatric patients, compared to age-related controls. Strikingly, plasma DBI is much higher (+ 81%, P <0.001) in generalized epilepsy in adults and in drug-resistant pediatric and adult patients. Based on these findings, plasma DBI may be considered as a peripheral biological marker of epilepsy and, in association with lymphocyte benzodiazepine receptor density, of anticonvulsant drug responsiveness.
- Diazepam binding inhibitor
- Drug resistance
- Peripheral benzodiazepine receptors
ASJC Scopus subject areas
- Clinical Neurology
- Pediatrics, Perinatology, and Child Health